LSB Industries, Inc. (LXU) Forms $6.94 Double Top; Ocular Therapeutix (OCUL) Shorts Lowered By 3.68%

August 1, 2017 - By Maria Brooks

Ocular Therapeutix Incorporated (NASDAQ:OCUL) had a decrease of 3.68% in short interest. OCUL’s SI was 5.91 million shares in August as released by FINRA. Its down 3.68% from 6.13M shares previously. With 645,200 avg volume, 9 days are for Ocular Therapeutix Incorporated (NASDAQ:OCUL)’s short sellers to cover OCUL’s short positions. The SI to Ocular Therapeutix Incorporated’s float is 25.99%. About 55,863 shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 9.50% since August 1, 2016 and is downtrending. It has underperformed by 26.20% the S&P500.

LSB Industries, Inc. (LXU) formed double top with $7.56 target or 9.00% above today’s $6.94 share price. LSB Industries, Inc. (LXU) has $197.13M valuation. About 85,041 shares traded. LSB Industries, Inc. (NYSE:LXU) has declined 34.80% since August 1, 2016 and is downtrending. It has underperformed by 51.50% the S&P500.

Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.31, from 1.38 in 2016Q3. It dived, as 23 investors sold LSB Industries, Inc. shares while 33 reduced holdings. 21 funds opened positions while 39 raised stakes. 18.71 million shares or 13.70% less from 21.68 million shares in 2016Q3 were reported. Moreover, Arizona State Retirement Systems has 0% invested in LSB Industries, Inc. (NYSE:LXU). State Teachers Retirement System holds 0% of its portfolio in LSB Industries, Inc. (NYSE:LXU) for 39,582 shares. Tower Ltd Company (Trc) holds 0% or 3,256 shares in its portfolio. Barrow Hanley Mewhinney Strauss Ltd Liability has invested 0% in LSB Industries, Inc. (NYSE:LXU). Point72 Asia (Hong Kong) owns 0% invested in LSB Industries, Inc. (NYSE:LXU) for 80 shares. Moreover, Thrivent Finance For Lutherans has 0% invested in LSB Industries, Inc. (NYSE:LXU). Ls Inv Advsrs Limited Liability Co stated it has 0% in LSB Industries, Inc. (NYSE:LXU). 27,215 are owned by Blackrock Grp Inc. Renaissance Technology Lc stated it has 148,200 shares. Bridgeway Capital Mgmt owns 30,000 shares. Sterneck Capital Mgmt Limited has invested 0.65% in LSB Industries, Inc. (NYSE:LXU). Tci Wealth Advsrs holds 99 shares. Gp One Trading L P owns 1,079 shares or 0% of their US portfolio. Gemmer Asset Management stated it has 424 shares. Gendell Jeffrey L owns 2.05% invested in LSB Industries, Inc. (NYSE:LXU) for 2.10 million shares.

Among 3 analysts covering LSB Industries (NYSE:LXU), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. LSB Industries had 4 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Strong Sell” rating by ValuEngine on Thursday, May 25. As per Wednesday, March 2, the company rating was upgraded by Feltl & Co. Zacks downgraded the shares of LXU in report on Thursday, August 13 to “Hold” rating. On Wednesday, March 9 the stock rating was maintained by Avondale with “Market Outperform”.

Among 7 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Ocular Therapeutix had 15 analyst reports since August 5, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, November 15 report. The firm has “Overweight” rating by Morgan Stanley given on Thursday, February 18. The firm has “Buy” rating by Nomura given on Wednesday, August 5. Cantor Fitzgerald maintained Ocular Therapeutix Inc (NASDAQ:OCUL) on Wednesday, July 12 with “Overweight” rating. Morgan Stanley maintained the shares of OCUL in report on Friday, July 14 with “Equal-Weight” rating. The rating was maintained by BTIG Research with “Hold” on Tuesday, July 11. Morgan Stanley downgraded Ocular Therapeutix Inc (NASDAQ:OCUL) on Friday, October 23 to “Equal-Weight” rating. The company was initiated on Thursday, August 13 by Morgan Stanley. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) earned “Overweight” rating by Morgan Stanley on Tuesday, June 7. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Equal-Weight” rating given on Friday, June 23 by Morgan Stanley.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The company has market cap of $183.17 million. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. It currently has negative earnings. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.